From MHRA Drug Safety Update:
Mirabegron is now contraindicated in patients with severe uncontrolled hypertension; advice about regular monitoring is being introduced because of cases of severe hypertension.
Advice for healthcare professionals from the MHRA:
- Mirabegron is contraindicated in patients with severe uncontrolled hypertension (systolic blood pressure ≥180mmHg or diastolic blood pressure ≥110mmHg, or both)
- Blood pressure should be measured before starting treatment and monitored regularly during treatment, especially in patients with hypertension
- Please report suspected side effects to mirabegron on a Yellow Card